Compare LOOP & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOOP | MAIA |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.1M | 44.9M |
| IPO Year | N/A | 2022 |
| Metric | LOOP | MAIA |
|---|---|---|
| Price | $0.90 | $1.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 94.8K | ★ 911.7K |
| Earning Date | 01-13-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,112,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,035.09 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10901.98 | N/A |
| 52 Week Low | $0.85 | $0.87 |
| 52 Week High | $2.29 | $2.74 |
| Indicator | LOOP | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 31.14 | 46.50 |
| Support Level | $1.02 | $1.07 |
| Resistance Level | $1.07 | $1.75 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 1.29 | 12.50 |
Loop Industries Inc. is a technology and licensing company whose mission is to accelerate the world's shift toward sustainable plastic and away from dependence on fossil fuels. The company owns patented and proprietary technology that depolymerizes no and low value waste PET plastic and polyester fiber, including plastic bottles and packaging, carpet and polyester textile of any color, transparency or condition, and even ocean plastics that have been degraded by the sun and salt, to its base building blocks.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.